16 Jun 2016 11:39
PuriCore plc
("PuriCore" or the "the Company")
Results of 2016 Annual General Meeting
16 June 2016 - PuriCore plc (AIM: PURI), an emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces that all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's investor website at http://investor.puricore.com.
Enquiries:
PuriCore plc | +44 (0) 20 3727 1000 |
Alex Martin, Chief Executive Officer | |
Marella Thorell, Chief Financial Officer and Chief Operating Officer | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan / Victoria Foster Mitchell | |
N+1 Singer (Nominated Adviser and Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell / Jen Boorer |
About PuriCore
PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated a drug development program, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology, Ophthalmology and potentially rare diseases. PuriCore also currently serves the Supermarket Retail and Wound Care markets with different technologies and formulations. For more details, go to our website: www.puricore.com